Business Wire

GLYPHOSATE-TASK-FORCE

16.5.2016 17:57:32 CEST | Business Wire | Press release

Share
GTF: WHO Body Concludes That Glyphosate is Unlikely to Pose a Carcinogenic Risk

The extraordinary meeting of the Joint FAO/WHO Meeting on Pesticide Residues (JMPR), held in Geneva from 9-13 May, has concluded that glyphosate is “unlikely to pose a carcinogenic risk to humans from exposure through the diet.”

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160516006224/en/

Glyphosate was scheduled for re-evaluation at the 2016 extraordinary meeting of the JMPR, based on recommendations of the JMPR 2015.

Richard Garnett, the chair of the Glyphosate Task force (GTF), said: “The GTF is not surprised that the JMPR has provided a review and conclusion that confirms the many previous assessments of glyphosate by regulatory agencies around the world.”

In the summary, published today, the JMPR concludes that glyphosate presents a very low acute toxicity and that glyphosate is not associated with genotoxic effects in an overwhelming majority of studies conducted in mammals. The summary concludes that glyphosate is unlikely to pose a carcinogenic risk to humans from exposure through the diet.

As the GTF we welcome the constant reviews of glyphosate and reiterate that a high level scrutiny only contributes to higher protection for consumers and operators,” said Garnett.

About the GTF:

The European Glyphosate Task Force (GTF) is a consortium of companies joining resources and efforts in order to renew the European glyphosate registration with a joint submission. This consortium is not to be considered a legal entity. The following companies are confirmed member of the GTF: ADAMA Agan Ltd., Agria S.A., Agro Trade GmbH, Albaugh UK Limited, Arysta Lifesciences SAS, Barclay Chemicals (Manufacturing) Ltd., Brokden SL, Bros Spolka Jawna B. P. Miranowscy, Cheminova A/S, Coromandel International Ltd, Dow AgroSciences LLC., EXCEL CROP CARE(Europe) NV, Helm AG, Industrias Afrasa S.A., Monsanto Europe S.A./N.V., Nufarm GmbH & Co KG, Rotam Agrochemical Europe Limited, Sapec Agro S.A., Sinon Corporation, Société Financière de Pontarlier, Syngenta Limited, United Phosphorus Ltd, Wynca UK Limited. For more information please see: www.glyphosate.eu

Contact:

For Glyphosate Task Force
Claire MacCarrick, +353.086.411.7461

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Reply Selected by Microsoft as Launch Partner for Agent 365, Supporting the Governance and Scaling of AI agents8.4.2026 10:17:00 CEST | Press release

Reply [EXM, STAR: REY] has been confirmed one of a small number of Launch Partners for Agent 365, supporting the general availability of Microsoft's new platform designed to provide enterprise-grade governance, observability and lifecycle management for AI agents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260408212380/en/ Through this collaboration with Microsoft, Reply reinforces its commitment to enabling organisations to implement artificial intelligence responsibly and at scale, supporting long-term digital transformation objectives. Microsoft Agent 365 introduces a structured framework enabling organisations to deploy, monitor and manage AI agents consistently across business functions. As artificial intelligence becomes embedded in core operational processes, Agent 365 provides clarity, control and accountability, ensuring that AI-driven activities remain transparent, secure and aligned with organisational objecti

HPE Takes Licence to Patents Offered Through the Sisvel Wi-Fi Multimode Pool8.4.2026 10:00:00 CEST | Press release

Hewlett Packard Enterprise (HPE) has become the latest company to take a licence to the patents offered through the recently launched Sisvel Wi-Fi Multimode pool. It joins Sony Group Corporation, Huawei, Panasonic, Philips and ZTE as a licensee of the programme. The latter four are also licensors, along with KPN, Mitsubishi Electric, Orange, Aegis 11 SA (a Sisvel affiliate), SK Telecom and Wilus. HPE is a major presence in the global WLAN market and is a leading manufacturer of both consumer and enterprise routers. The deal with Sisvel was reached on an amicable basis. The Sisvel Wi-Fi Multimode pool is the successor programme to the Sisvel Wi-Fi 6 patent pool. Over a three-year period, this closed agreements with nearly 40 companies, including Acer, Netgear, Cisco and HP. Covering Wi-Fi 7 as well as 6, the Multimode programme offers an efficient way to access essential Wi-Fi rights for years to come. “We are delighted to welcome Hewlett Packard Enterprise as the latest licensee of the

Zyxel and Openreach Team Up to Reduce Plastic Waste in Full Fibre Installations8.4.2026 10:00:00 CEST | Press release

A new partnership between Zyxel Communications and Openreach is helping to cut plastic and packaging waste from the UK’s Full Fibre rollout - by deploying re-cycled ‘modems’ to connect customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260408766604/en/ Openreach - GPON ONT Zyxel is deploying a range of new Optical Network Terminals (ONTs) - the wall-mounted box of electronics that converts optical signals into electrical ones used by household devices - with re-engineered casings made from 95 per cent recycled plastic.1 Openreach engineers have already installed half a million of Zyxel’s sustainable ONTs and the network provider expects to install even more this year as customers upgrade to Full Fibre - the UK’s most reliable broadband technology. The GPON2 devices use recycled plastic in their construction and arrive in zero‑plastic minimal packaging made from recycled materials. Openreach is working with Zyxel and o

Jeito Capital Hits Record $1.2 Billion (€1 Billion)1 Close for Jeito II Fund to Drive Breakthrough Therapeutic Innovation for Patients8.4.2026 08:15:00 CEST | Press release

This record closing is the largest raise ever achieved by a fully independent European fund dedicated to Biopharma, validating Jeito’s patient-driven investment strategy, its multidisciplinary, collaborative expertise spanning from science to commercialization of medicines, and value creationIn five years, Jeito Capital has tripled its assets under management to €1.6 billion, firmly establishing itself among the top-tier global Biopharma investorsJeito II will build on Jeito I’s proven and differentiated strategy, investing in the most promising clinical Biopharma companies which address unmet patient needs and severe diseases, accelerate breakthrough therapeutic innovation, and deliver transformative benefits for patientsThis fundraise represents significant momentum for European Biopharma, strengthening its financial firepower and expertise to develop the next generation of global champions Jeito Capital (“Jeito”), a global independent private equity fund dedicated to Biopharma, toda

Croma-Pharma Acquires Synocrom™ and Returns to Orthopaedics8.4.2026 07:00:00 CEST | Press release

Hyaluronic acid product for knee osteoarthritis available in the EU and Switzerland from May 2026 Croma-Pharma is returning to the orthopaedics market with the reacquisition of Synocrom™, a hyaluronic acid product for the treatment of knee osteoarthritis. A strategic return built on proven heritage With the reacquisition of Synocrom™, Croma-Pharma is re-entering orthopaedics and further broadening its portfolio in a field with strong historical roots for the company. Until 2014, Croma was active in orthopaedics, with Synocrom™ serving as a key pillar of its offering. Synocrom™ is not a new name in the market. During the period in which Croma actively marketed the product, it became one of the leading hyaluronic acid brands in Europe and ranked among the top brands in its category. Its return therefore represents more than a portfolio expansion: it marks the continuation of a successful orthopaedic legacy and reconnects Croma with an important part of its history. The reintroduction of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye